CSIMarket
 


Pliant Therapeutics Inc   (PLRX)
Other Ticker:  
 
 

PLRX's Net Cash Flow Growth by Quarter and Year

Pliant Therapeutics Inc 's Net Cash Flow results by quarter and year




PLRX Net Cash Flow (in millions $) FY 2023 FY 2022 FY 2021 FY 2020
IV Quarter December - -10.93 6.43 -4.34
III Quarter September 2.73 19.55 10.04 -123.24
II Quarter June -47.58 -7.48 -15.63 92.65
I Quarter March 68.84 -19.12 -0.06 0.00
FY   23.99 -17.98 0.78 -34.93



PLRX Net Cash Flow third quarter 2023 Y/Y Growth Comment
Pliant Therapeutics Inc reported drop in Net Cash Flow in the third quarter 2023 by -86.05% to $ 2.73 millions, from the same quarter in 2022.
The fall in the third quarter 2023 Pliant Therapeutics Inc 's Net Cash Flow compares unfavorably to the Company's average Net Cash Flow growth of 4.33%.

Looking into third quarter 2023 results within Major Pharmaceutical Preparations industry 74 other companies have achieved higher Net Cash Flow growth. While Pliant Therapeutics Inc ' s Net Cash Flow meltdown of -86.05% ranks overall at the positon no. 899 in the third quarter 2023.




PLRX Net Cash Flow ( Y/Y Growth %) 2023
2022 2021 2020
IV Quarter December - - - -
III Quarter September -86.05 % 94.72 % - -
II Quarter June - - - -
I Quarter March - - - -
FY   - - - -

Financial Statements
Pliant Therapeutics Inc 's third quarter 2023 Net Cash Flow $ 2.73 millions PLRX's Income Statement
Pliant Therapeutics Inc 's third quarter 2022 Net Cash Flow $ 19.55 millions Quarterly PLRX's Income Statement
New: More PLRX's historic Net Cash Flow Growth >>


PLRX Net Cash Flow (Quarter on Quarter Growth %)

2023
2022 2021 2020
IV Quarter December - - -35.96 % -
III Quarter September - - - -
II Quarter June - - - -
I Quarter March - - - -
FY (Year on Year)   - - - -




Net Cash Flow third quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #75
Healthcare Sector #153
Overall #899

Net Cash Flow Y/Y Growth Statistics
High Average Low
94.71 % 4.33 % -86.04 %
(Sep 30 2022)   (Sep 30 2023)
Net Cash Flow third quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #75
Healthcare Sector #153
Overall #899
Net Cash Flow Y/Y Growth Statistics
High Average Low
94.71 % 4.33 % -86.04 %
(Sep 30 2022)   (Sep 30 2023)

Net Cash Flow by Quarter for the Fiscal Years 2020, 2021, 2022, 2023

Pliant Therapeutics Inc 's Q/Q Net Cash Flow Growth


Net Cash Flow Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


PLRX's III. Quarter Q/Q Net Cash Flow Comment
III. Quarter 2023Seasonal Pliant Therapeutics Inc in the circumstances net cash outflow of $ 2.73 millionsSeasonal circumstances appear to have led to Pliant Therapeutics Inc 's restoration of recovery, as PLRX clinchesNet Cash Flow of $ 2.73 millions in the III. Quarter 2023 emanate net cash outflow-47.58 millions in the second quarter. Pliant Therapeutics Inc announced in the III. Quarter 2023 Net Cash Flow of $ 2.73 millions compare to net cash outflow recorded in previos quarter.

Within Major Pharmaceutical Preparations industry Pliant Therapeutics Inc achieved highest sequential Net Cash Flow growth. While Pliant Therapeutics Inc 's Net Cash Flow growth quarter on quarter, overall rank is .


Net Cash Flow Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Net Cash Flow Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Net Cash Flow Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


PLRX's III. Quarter Q/Q Net Cash Flow Comment
III. Quarter 2023Cyclical Pliant Therapeutics Inc in the circumstances net cash outflow of $ 2.73 millionsCyclical circumstances appear to have led to Pliant Therapeutics Inc 's restoration of recovery, as PLRX postNet Cash Flow of $ 2.73 millions in the III. Quarter 2023 emerging from net cash outflow-47.58 millions in the second quarter. Pliant Therapeutics Inc announced in the III. Quarter 2023 Net Cash Flow of $ 2.73 millions compare to net cash outflow recorded in previos quarter.

Within Major Pharmaceutical Preparations industry Pliant Therapeutics Inc achieved highest sequential Net Cash Flow growth. While Pliant Therapeutics Inc 's Net Cash Flow growth quarter on quarter, overall rank is .


Pliant Therapeutics Inc 's 12 Months Net Cash Flow Growth Year on Year


Net Cash Flow TTM Growth

12 Months Ending
(Sep 30 2023)
12 Months Ending
(Jun 30 2023)
12 Months Ending
(Mar 31 2023)
12 Months Ending
(Dec 31 2022)
12 Months Ending
(Sep 30 2022)
Cumulative Net Cash Flow 12 Months Ending $ 13.06 $ 29.88 $ 69.98 $ -17.98 $ -0.61
Y / Y Net Cash Flow Growth (TTM) - - - - -
Year on Year Net Cash Flow Growth Overall Ranking # # # # #
Seqeuential Net Cash Flow Change (TTM) -56.29 % -57.3 % - - -
Seq. Net Cash Flow Growth (TTM) Overall Ranking # 344 # 418 # 0 # 0 # 0




Cumulative Net Cash Flow growth Comment
In the Sep 30 2023 period, Pliant Therapeutics Inc had cumulative twelve months Net Cash Flow of $ 13 millions compare to net cash outflow of $ -1 millions a year ago.

Pliant Therapeutics Inc achieved highest trailing twelve month year on year Net Cash Flow growth. While overall Net Cash Flow growth ranking, remained unchanged compare to the previous quarter at no. .

Net Cash Flow TTM Q/Q Growth Statistics
High Average Low
-2396.42 %
-2396.42 %
-2396.42 %
 

Net Cash Flow TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Net Cash Flow TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Net Cash Flow TTM Q/Q Growth Company Ranking
Within: No.
Industry # 20
Sector # 59
S&P 500 # 344
Cumulative Net Cash Flow growth Comment
In the Sep 30 2023 period, Pliant Therapeutics Inc had cumulative twelve months Net Cash Flow of $ 13 millions compare to net cash outflow of $ -1 millions a year ago.

Pliant Therapeutics Inc achieved highest trailing twelve month year on year Net Cash Flow growth. While overall Net Cash Flow growth ranking, remained unchanged compare to the previous quarter at no. .

Net Cash Flow TTM Q/Q Growth Statistics
High Average Low
-2396.42 %
-2396.42 %
-2396.42 %
 


Net Cash Flow TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Net Cash Flow TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Net Cash Flow TTM Q/Q Growth Company Ranking
Within: No.
Industry # 20
Sector # 59
S&P 500 # 344




Other Net Cash Flow Growth
Major Pharmaceutical Preparations Industry Net Cash Flow Growth Trends and Statistics
Healthcare Sector Net Cash Flow Growth Statistics
Net Cash Flow Growth Trends for overall market
PLRX's Net Cash Flow Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Net Cash Flow Growth
Lowest Ranking Net Cash Flow Growth
Net Cash Flow Growth for PLRX's Competitors
Net Cash Flow Growth for Pliant Therapeutics Inc 's Suppliers
Net Cash Flow Growth for PLRX's Customers

You may also want to know
PLRX's Annual Growth Rates PLRX's Profitability Ratios PLRX's Asset Turnover Ratio PLRX's Dividend Growth
PLRX's Roe PLRX's Valuation Ratios PLRX's Financial Strength Ratios PLRX's Dividend Payout Ratio
PLRX's Roa PLRX's Inventory Turnover Ratio PLRX's Growth Rates PLRX's Dividend Comparisons



Companies with similar Net Cash Flow meltdown for the quarter ending Sep 30 2023 within Healthcare SectorY/Y Change %Net Cash Flow for the quarter ending Sep 30 2023
Nascent Biotech Inc-4.04%$ -4.038 millions
Halozyme Therapeutics Inc -5.63%$ -5.629 millions
Vystar Corporation-6.05%$ -6.052 millions
Ideaya Biosciences Inc -7.27%$ -7.268 millions
Phibro Animal Health Corporation-7.87%$ -7.874 millions
Luna Innovations Inc-9.06%$ -9.058 millions
Puma Biotechnology Inc -13.53%$ -13.534 millions
Fulgent Genetics Inc -14.21%$ -14.211 millions
Prestige Consumer Healthcare Inc -16.52%$ -16.522 millions
Omniab Inc -20.57%$ -20.566 millions
Gossamer Bio Inc -22.91%$ -22.914 millions
Alnylam Pharmaceuticals Inc -24.60%$ -24.599 millions
Emmaus Life Sciences Inc -26.90%$ -26.904 millions
Kala Bio inc -27.38%$ -27.384 millions
Protara Therapeutics Inc -29.54%$ -29.540 millions
Msa Safety Incorporated-31.72%$ -31.716 millions
Avalo Therapeutics Inc -32.14%$ -32.143 millions
Biovie Inc -32.27%$ -32.265 millions
Veracyte inc -32.97%$ -32.966 millions
Coherus Biosciences inc -35.07%$ -35.068 millions
Biomarin Pharmaceutical Inc-35.76%$ -35.762 millions
International Stem Cell Corporation-40.00%$ -40.000 millions
Arvinas Inc -42.82%$ -42.822 millions
89bio Inc -44.85%$ -44.846 millions
Assertio Holdings inc -46.56%$ -46.561 millions
Infusystem Holdings Inc-48.08%$ -48.077 millions
Eqrx Inc -48.96%$ -48.965 millions
Privia Health Group Inc -49.62%$ -49.617 millions
Nektar Therapeutics-49.69%$ -49.693 millions
Avinger Inc -53.79%$ -53.788 millions




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com